Ouro Medicines
Ouro Medicines is a biotechnology company developing immune reset therapeutics. Its lead candidate, gamgertamig, has FDA Fast Track designation.
Secondary Market Price
How Ouro Medicines Measures Up
To help you manage your Ouro Medicines equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series A
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Ouro Medicines's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Ouro Medicines Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Ouro Medicines's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Ouro Medicines is a clinical-stage biotechnology company developing immune reset therapeutics for people with chronic immune-mediated diseases. The company's approach focuses on leveraging T cell engagers in B cell mediated diseases. Its lead candidate, OM336 (also known as gamgertamig), is a BCMAxCD3 T cell engager antibody currently in a multinational Phase 1b basket study for autoimmune cytopenias, Sjögren’s disease, and idiopathic inflammatory myopathies. Ouro Medicines was founded in San Francisco in 2024 by Monograph Capital in partnership with GSK and is backed by investors including TPG, NEA, and Norwest.
The company plans to continue advancing OM336 through clinical development, with results from its Phase 1b studies expected in 2026. Ouro Medicines has received multiple recent FDA designations for its lead candidate, including Fast Track designation for autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP), as well as Orphan Drug Designation for both conditions. The company has also initiated a collaboration with THREAD to implement remote monitoring in its clinical trials and was recognized as one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2025.
- TPG Life Sciences Innovations
- New Enterprise Associates
- Norwest Venture Partners
- Monograph Capital
- GSK
- UPMC Enterprises
- Boyu/Zoo Capital
- LongRiver Investments
- Co-Founder, Jaideep Dudani
- Co-Founder, Monograph Capital
- Co-Founder, GSK
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Ouro Medicines worth joining?
Deciding whether to join a company like Ouro Medicines depends on your personal career goals and financial situation. Tools like Prospect can help you evaluate your potential equity compensation by modeling its future value, giving you a clearer picture of the financial opportunity.
What should I do with my Ouro Medicines stock?
The right strategy for your Ouro Medicines stock depends on your personal financial goals, tax situation, and the company's performance. Platforms like Prospect can provide customized strategies for exercising options and selling shares to help you maximize your returns.
Can you sell Ouro Medicines stock?
Selling stock in a private company like Ouro Medicines is typically possible during specific liquidity events, such as a tender offer, or on secondary markets. Prospect offers tender offer tools to help you decide how much to sell and which shares are the most tax-optimal.
How can I find the value of my Ouro Medicines stock?
Valuing stock in a private company is challenging because it isn’t publicly traded and its price isn't readily available. Prospect uses proprietary models trained on venture capital data to project the future value of your shares and help you understand what your equity could be worth.
What is Ouro Medicines's equity worth?
The worth of your Ouro Medicines equity is based on the company's current valuation and potential future growth, minus any taxes you'll owe upon exercising or selling. You can use a platform like Prospect to model different scenarios and forecast your potential post-tax earnings from your equity.
What is Ouro Medicines's stock ticker symbol?
As a private, pre-IPO company, Ouro Medicines does not have a stock ticker symbol. Ticker symbols are assigned to companies only when they become publicly traded on a stock exchange.
Can I buy or sell Ouro Medicines stock?
Employees can typically "buy" stock by exercising their vested options, and selling is usually possible during company-approved tender offers or on secondary markets. Prospect provides personalized option exercise strategies and tools to help you navigate sales opportunities effectively.
What is the criteria to buy or invest in Ouro Medicines stock?
For employees, the opportunity to buy stock is typically through exercising vested options, and the decision depends on your personal financial situation and risk tolerance. Prospect helps you analyze this decision by modeling the return on investment and tax implications of exercising your options.
